EXCLUSIVE: Alzamend Neuro Tells Benzinga Co. Has Identified A Maximum Tolerated Dose For Development Of Al001 From A Multiple-Ascending Dose Study As Assessed By An Independent Safety Review Committee
Portfolio Pulse from Benzinga Newsdesk
Alzamend Neuro has identified a maximum tolerated dose for the development of AL001 from a multiple-ascending dose study, as assessed by an independent safety review committee.
June 22, 2023 | 11:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alzamend Neuro's identification of a maximum tolerated dose for AL001 development may positively impact the company's stock price.
The identification of a maximum tolerated dose for AL001 development is a significant milestone for Alzamend Neuro. This progress may lead to increased investor confidence and a potential rise in the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100